about
Executive Summary: Heart Disease and Stroke Statistics--2012 Update: A Report From the American Heart AssociationHeart Disease and Stroke Statistics--2015 Update: A Report From the American Heart AssociationUsing a tailored health information technology- driven intervention to improve health literacy and medication adherence in a Pakistani population with vascular disease (Talking Rx) - study protocol for a randomized controlled trial.Heart disease and stroke statistics--2014 update: a report from the American Heart AssociationOverview of Coronary Heart Disease Risk Initiatives in South AsiaEvaluating Periodontal Treatment to Prevent Cardiovascular Disease: Challenges and Possible Solutions.Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies.Segmental analysis of carotid arterial strain using speckle-tracking.The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).Calculations of Financial Incentives for Providers in a Pay-for-Performance Program: Manual Review Versus Data From Structured Fields in Electronic Health Records.Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) studyWhat is new in the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic risk in adults?Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemiaBarriers to non-HDL cholesterol goal attainment by providers.Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study.Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study.Metrics of quality care in veterans: correlation between primary-care performance measures and inappropriate myocardial perfusion imaging.Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) studyLPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.Cardiovascular Disease Performance Measures in the Outpatient Setting in India: Insights From the American College of Cardiology's PINNACLE India Quality Improvement Program (PIQIP).A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies.Effect of Long-Term Periodontal Care on Hemoglobin A1c in Type 2 Diabetes.Treating chronically ill people with diabetes mellitus with limited life expectancy: implications for performance measurementStatin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database.Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry.Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.Cardiovascular disease risk by assigned treatment using the 2013 and 1998 obesity guidelinesApplication of speckle-tracking in the evaluation of carotid artery function in subjects with hypertension and diabetesNovel markers of inflammation in atherosclerosis.The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components.Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region.Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis.Chromosome 9p21 single nucleotide polymorphisms are not associated with recurrent myocardial infarction in patients with established coronary artery diseaseEconomic Impact of Moderate-Vigorous Physical Activity Among Those With and Without Established Cardiovascular Disease: 2012 Medical Expenditure Panel Survey.Lipid management: considerations in acute coronary syndrome.Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG-CAD) Registry.Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study.Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.
P50
Q22241920-B912949B-D9DD-4578-A780-73AC965ABBDFQ22241921-E741668E-EA76-4D59-BBE1-3F2DD09CEB61Q27334398-97AAD1AB-A1DC-438C-999C-5DE26796C7F1Q29547691-44C62507-8EA4-4730-A30F-47CFD53E86D6Q29994620-5F75757C-41C3-4C78-9EC9-31E0393865DAQ30238793-35F3A935-EA69-4174-9A10-192CAA493EB8Q30245421-C75CBE17-9FF0-4E6F-B860-884912B878B9Q30461867-37E41FC2-00BA-4916-B35A-C3706CAE4E2CQ30662013-941A1A3D-D8CC-43D6-A055-2D1CF5ED85E7Q30974832-BEB7D011-CA9C-41E3-8E2E-DD5655643B9CQ30991583-57396487-9253-4FAB-838F-6B584F98F16DQ33693760-1F8C08AA-C350-4E9F-85E8-32FB314D9CA8Q33766170-EC31F9D3-0329-40D8-9796-A888C53C0E84Q33833360-E783B680-58B7-4670-8F09-D405B6B8AF0DQ34270897-0D4DDA5B-2FF1-464A-9C56-BE54A316690DQ34505315-4742BD02-83EF-4284-BFD7-6C41EB83B743Q34789650-9B528773-33F2-4D11-A114-48BA1F4D393BQ35102964-47C03951-3FD8-4D2A-B10E-F414312BC06FQ35537103-1664C09D-47C8-4807-9768-A224CCA3ECEBQ35635548-0D48192C-FDA4-42AE-AD0B-4290A875E54AQ35747811-3562973E-039D-4EA3-95AF-85CD485546CEQ36141396-BFDAB269-48DE-4EEC-ABE3-7E78506224ADQ36677207-60B49E1C-28E4-43CF-8838-956805ABCA56Q36714878-0F49D720-80A1-4314-BD7B-7AEEE36B7183Q36738051-C137E8F0-3C8B-43B7-8DD3-AF3037E53C62Q36823179-522470FB-61DB-4186-ABCF-896AEF826CFDQ36915679-226D3A4D-4098-486A-85C8-1D1AF83E7FC2Q36920620-34256235-E470-4D85-961D-50DAAFA28873Q37047729-1818C2C9-42D7-4B3E-88AA-F1E28C3C8EA5Q37049840-5DFF0328-3EAD-419C-B2D1-6AFFC7DFC7A0Q37140097-6F8E7374-4158-4786-BA43-E6C7EFB95866Q37164158-F733B225-6085-4A3B-995D-37942DCB89F9Q37193537-ECB77E2E-E2E2-46D0-8772-A7970FBAF524Q37239358-BB30943E-19F9-445F-9068-D8D146EAE301Q37334411-C94AD259-4974-4A75-AE56-33FB9D1B0B6CQ37364428-3E45B101-8D23-4C9F-9FCD-3F39E6484B16Q37396588-B49A1D5E-FFBA-490D-A346-A63EA16DB65FQ37434741-B4FD8C02-B7EA-482D-9D89-85A267D79EBAQ37538062-20637F0D-E93C-456A-B6C7-94904800E4B2Q37573986-47B55FBB-9F82-4274-A8A7-55904CD76D0C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Salim S Virani
@es
Salim S Virani
@nl
Salim S Virani
@sl
Salim S. Virani
@en
type
label
Salim S Virani
@es
Salim S Virani
@nl
Salim S Virani
@sl
Salim S. Virani
@en
prefLabel
Salim S Virani
@es
Salim S Virani
@nl
Salim S Virani
@sl
Salim S. Virani
@en
P106
P1153
6701757915
P21
P31
P496
0000-0001-9541-6954
P569
2000-01-01T00:00:00Z